MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: Association with FUS gene rearrangement

American Journal of Surgical Pathology

Volumn 36, Issue 10, 2012, Pages 1444-1451

  Doyle, Leona A ^a   Wang, Wei Lien ^b   Dal Cin, Paola ^a   Lopez Terrada, Dolores ^c   Mertens, Fredrik ^d   Lazar, Alexander J F ^b   Fletcher, Christopher D M ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FISH; immunohistochemistry; sarcoma; soft tissue tumors; translocation

Indexed keywords

MUC4 PROTEIN, HUMAN; MUCIN 4; RNA BINDING PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DIFFERENTIAL DIAGNOSIS; EPITHELIOID CELL; FEMALE; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MULTIPLE CANCER; PATHOLOGY; SCLEROSIS; SOFT TISSUE TUMOR; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGED; CHILD; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; FEMALE; FIBROSARCOMA; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUCIN-4; NEOPLASMS, MULTIPLE PRIMARY; RNA-BINDING PROTEIN FUS; SARCOMA, SYNOVIAL; SCLEROSIS; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84866611741     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182562bf8     Document Type: Article

References (37)

1. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7:4033-4040.
2. Antonescu CR, Rosenblum MK, Pereira P, et al. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol. 2001;25: 699-709.
3. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893-2904.
4. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol. 2002;71:149-185.
5. Carraway KL, Theodoropoulos G, Kozloski GA, et al. Muc4/MUC4 functions and regulation in cancer. Future Oncol. 2009;5: 1631-1640.
6. Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008;22:966-981.
7. Chaturvedi P, Singh AP, Chakraborty S, et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008;68:2065-2070.
8. Doyle LA, Moller E, Dal Cin P, et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011;35:733-741.
9. Dvornik G, Barbareschi M, Gallotta P, et al. Low grade fibromyxoid sarcoma. Histopathology. 1997;30:274-276.
10. Enzinger FM, Weiss SW, Liang CY. Ossifying fibromyxoid tumor of soft parts. A clinicopathological analysis of 59 cases. Am J Surg Pathol. 1989;13:817-827.
11. Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol. 1987;88:615-619.
12. Evans HL. Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol. 1993;17:595-600.
13. Evans HL. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up. Am J Surg Pathol. 2011;35:1450-1462.
14. Eyden BP, Manson C, Banerjee SS, et al. Sclerosing epithelioid fibrosarcoma: a study of five cases emphasizing diagnostic criteria. Histopathology. 1998;33:354-360.
15. Folk GS, Williams SB, Foss RB, et al. Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases. Head Neck Pathol. 2007;1:13-20.
16. Folpe AL, Lane KL, Paull G, et al. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol. 2000;24:1353-1360.
17. Gisselsson D, Andreasson P, Meis-Kindblom JM, et al. Amplification of 12q13 and 12q15 sequences in a sclerosing epithelioid fibrosarcoma. Cancer Genet Cytogenet. 1998;107:102-106.
18. Goodlad JR, Mentzel T, Fletcher CD. Low grade fibromyxoid sarcoma: clinicopathological analysis of eleven new cases in support of a distinct entity. Histopathology. 1995;26:229-237.
19. Graham RP, Dry S, Li X, et al. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study. Am J Surg Pathol. 2011;35:1615-1625.
20. Guillou L, Benhattar J, Gengler C, et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007;31: 1387-1402.
21. Jagdis A, Rubin BP, Tubbs RR, et al. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009;33:1743-1751.
22. Jin Y, Moller E, Nord KH, et al. Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer. 2012;51:510-520.
23. Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol. 1995;19:979-993.
24. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408-415.
25. Miettinen M. Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol. 1991;138:505-513.
26. Miettinen M, Finnell V, Fetsch JF. Ossifying fibromyxoid tumor of soft parts\a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature. Am J Surg Pathol. 2008;32:996-1005.
27. Moller E, Hornick JL, Magnusson L, et al. FUS-CREB3L2/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. Clin Cancer Res. 2011;17: 2646-2656.
28. Ogose A, Kawashima H, Umezu H, et al. Sclerosing epithelioid fibrosarcoma with der(10)t(10;17)(p11;q11). Cancer Genet Cyto-genet. 2004;152:136-140.
29. Panagopoulos I, Storlazzi CT, Fletcher CD, et al. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer. 2004;40:218-228.
30. Park HU, Kim JW, Kim GE, et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas. 2003;26:e48-e54.
31. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005;18:1295-1304.
32. Reid R, Barrett A, Hamblen DL. Sclerosing epithelioid fibrosarco-ma. Histopathology. 1996;28:451-455.
33. Reid R, de Silva MV, Paterson L, et al. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation. Am J Surg Pathol. 2003;27:1229-1236.
34. Rekhi B, Folpe AL, Deshmukh M, et al. Sclerosing epithelioid fibrosarcoma-a report of two cases with cytogenetic analysis of FUS gene rearrangement by FISH technique. Pathol Oncol Res. 2011;17:145-148.
35. Singh AP, Chauhan SC, Bafna S, et al. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate. 2006;66:421-429.
36. Wang WL, Evans HL, Meis JM, et al. FUS rearrangements are rare in "pure" sclerosing epithelioid fibrosarcoma. Mod Pathol. 2012. Mar 2. doi: 10.1038/modpathol.2011.214. [Epub ahead of print].
37. Workman HC, Sweeney C, Carraway KL III. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res. 2009; 69:2845-2852.